Friday, April 16, 2010
Amrita Arora & Isha Goppikar Hot in Ragsiya Sinagithi Movie
Health Update :-
The U.S. Food and Drug Administration (FDA) is again alerting healthcare professionals that the prescription weight-loss drug sibutramine, marketed in the U.S. as Meridia, is contraindicated in patients with a history of cardiovascular disease, due to increase risk of heart attack and stroke.
Last January, at the behest of the FDA, Meridia’s manufacturer Abbott Laboratories agreed to add new contraindications on materials for the drug after reviewing additional data from the Sibutramine Cardiovascular Morbidity/Mortality Outcomes in Overweight or Obese Subjects at Risk of a Cardiovascular Event (SCOUT) study.
The SCOUT study, which began in 2002, was designed to show that weight loss with sibutramine and standard care was more effective in reducing the number of cardiovascular events compared to weight loss from a placebo and standard care. About 10,000 overweight or obese people, 55 years of age or older, who had a history of heart disease or type 2 diabetes plus one additional cardiovascular risk factor were enrolled in the study. Patients who recently had a heart attack or stroke, or had poorly controlled congestive heart failure were not included.